Pharmacists, parallel trade and the pandemic
This article was originally published in Scrip
Executive Summary
Parallel trade is guaranteed to cause controversy at the best of times. Pharmaceutical companies say that it deprives them of revenues in the importing country and benefits nobody but the parallel traders themselves. The traders counter that their business is perfectly legal within the EU and insist it helps bring down drug expenditures for both payers and patients.